We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Marinomed Biotech AG (MARI) NPV

Sell:€17.50 Buy:€17.80 Change: €0.75 (4.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€17.50
Buy:€17.80
Change: €0.75 (4.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€17.50
Buy:€17.80
Change: €0.75 (4.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.

Contact details

Address:
Hovengasse 25
KORNEUBURG
2100
Austria
Telephone:
+43 (2262) 90300
Website:
https://www.marinomed.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MARI
ISIN:
ATMARINOMED6
Market cap:
€28.42 million
Shares in issue:
1.54 million
Sector:
Pharmaceuticals
Exchange:
Vienna Stock Exchange
Country:
Austria
Currency:
Euro
Indices:
n/a

Key personnel

  • Simon Nebel
    Independent Chairman of the Supervisory Board
  • Andreas Grassauer
    Chairman of the Executive Board, Chief Executive Officer
  • Ute Lassnig
    Independent Deputy Chairman of the Supervisory Board
  • Pascal Schmidt
    Chief Financial Officer, Member of the Executive Board
  • Eva Prieschl- Grassauer
    Chief Scientific Officer, Member of the Executive Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.